Pharmaceutical
Indications

 

39 Results were found on Technologies

Leading Researchers:
10-2018-1153

An Oncolytic Virus That Exploits Immune Defects of Cancer Cells

An oncolytic virus for tumors of different etiology presenting defects in interferon signaling, designed as a potent, specific and safe therapy. Promising in-vivo murine melanoma model shows potential for development as a mono or an add-on to... Read More >

Leading Researchers:
10-2019-1235

Broad-Spectrum Metastasis Suppressing Compounds in Human Solid Tumors

Despite recent advances in cancer therapy, still malignancy is responsible for 15% of human death. Among these patients having solid tumors, 90% die from metastatic disease. Thus, effective prevention and suppression of metastasis is still an... Read More >

Leading Researchers:
2022-0194

Safe Peptides Against Candida and Fungi

Invasive candida and Fungi pose a series health threat. There is no vaccine and very limited treatment options with adverse side effects. Our technology is a series of safe peptides that can be used to treat candida or fungi infections via... Read More >

Leading Researchers:
10-2019-1337

Anti-Cancer Nanotherapy: Targeted Potent Conjugated BRAF/MEK Inhibitors

In the last decade, deep understanding of key oncogenes and signaling pathways, involved in cancer pathogenesis and progression were achieved, leading to new treatment options. However, the number of patients with metastatic melanoma continue... Read More >

Leading Researchers:
2-2022-1719

Repurposing FDA-Approved Drugs for the Treatment of Aniridia

Aniridia is a panocular disease causing progressive severe visual impairment and blindness. The disease is characterized by abnormal development of almost all eye structures, caused by dominantly inherited heterozygous mutations in primarily the... Read More >

Leading Researchers:
2-2016-991

A Novel Nanoparticle that Selectively Delivers RNAi Oligonucelotides to Tumors, Preventing Side Effects to Tissues

UNMET NEEDPancreatic cancer numbers among the most aggressive cancers known today. The overwhelming majority of pancreatic cancer patients pass away within just a year of diagnosis. However, a small minority of patients may live several years with... Read More >

Leading Researchers:
10-2021-1659

Novel Bcr-Abl1 Inhibitors for Treating Imatinib Resistance Cancer

The BCR-ABL1 fusion gene is the hallmark of the Philadelphia chromosome-positive (Ph+) leukemia, creating a constitutively active ABL1 tyrosine kinase. Current therapy relies on the FDA-approved tyrosine kinase inhibitors (TKIs) such as imatinib... Read More >

Leading Researchers:
2022-0195

Therapeutic Monoclonal Antibodies to Combat Multidrug-Resistant Pathogenic Bacteria

It is predicted that a failure to address the problem of antibiotic-resistant pathogens will result in the death of 10 million people annually, costing the economy more than 100 trillion dollars by the year 2050. In high-income countries where... Read More >

Leading Researchers:
5-2020-1362

An early stage screening tool for distinguishing pregnant women having an increased risk of developing preeclampsia

Preeclampsia is one of the most dangerous pregnancy complications occurs in the second or third trimester, affecting 3–8% of pregnancies; it is the leading cause of maternal and perinatal mortality and morbidity. Preeclampsia cannot reliably be... Read More >

Leading Researchers:
10-2020-1381

Dendritic Cell-Targeted Nanovaccine for SARS-CoV-2 with Incorporated Immune Potentiators

During the SARS-CoV-2 pandemic, nanoscale vaccine technologies (e.g., mRNA vaccines) have proven superiority over conventional vaccines in terms of production speed and modularity. Unfortunately, the restricted global distribution results in... Read More >